Check out what we have in store for you in the June Newsletter
The International Liver Congress (ILC) 2017 was held in April and this month we will feature Part 2 of our on-going coverage.
- Alan’s coverage includes: final results from a phase 3 study of glecaprevir plus pibrentasvir (one pill/once-a-day) to treat genotype 3; a phase 2 study of MK-3682/grazoprevir plus ruzasvir to treat people who previously failed direct-acting antiviral therapy; treatment with sofosbuvir/velpatasvir plus voxilaprevir (one-pill, once-a-day) in treatment experienced patients with resistance and finally a study comparing liver cancer outcomes in people achieving a cure with interferon-based therapies vs. direct-acting antiviral therapies.
- Lucinda’s coverage includes: high cure rates with legally imported generic HCV drugs; Harvoni in patients with HCV/HBV coinfection; Harvoni +/– ribavirin treatment in children with chronic hepatitis C and lastly physical activity and cardiorespiratory fitness levels in people living with hepatitis C.
- Matthew’s coverage includes: a study of a viral load point-of-care test that has the potential to improve the HCV treatment cascade and the long-term gender differences in outcomes among people with hepatitis B and hepatitis C.
- What’s Up! Have you listened to our new voiceovers? We have added voiceovers to some of our most popular Easy C fact sheets – check them out!
Peace, prosperity and good health,
Alan and the staff of the HCV Advocate